Natera, Inc. Common Stock (NTRA) — Analysis Summary
Natera, Inc. Common Stock (NTRA) has a market cap of $48.82B with year-over-year revenue growth of +35.9%. Net margin stands at -9.0%. The stock trades at a P/E ratio of -253.8.
Key Takeaways
- Revenue changed +35.9% year-over-year
- Net margin of -9.0%
- P/E ratio of -253.8
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, NTRA posted revenue growth of +35.9% and trades at a P/E of -253.8.
Natera, Inc. Common Stock (NTRA)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -75.9x — earnings do not cover interest payments
Operating margin at -10.7% — material operating losses
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
6,140
Headquarters
AUSTIN, TX
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.